Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 15;2(3):515-518.
doi: 10.1016/j.jaccao.2020.06.005. eCollection 2020 Sep.

CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy

Affiliations
Review

CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy

Anthony J Kanelidis et al. JACC CardioOncol. .
No abstract available

Keywords: CAR, chimeric antigen receptor; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; GDMT, guideline-directed medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction; PAd, pulmonary artery diastolic pressure; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; RHC, right heart catherization; TTE, transthoracic echocardiogram; anthracycline; cardiomyopathy; heart failure; immunotherapy; lymphoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CardioMEMS Pulmonary Artery Pressure Monitoring CardioMEMS guided diuretic administration and dosing (e.g., intravenous furosemide 20 mg [black triangles] and 40 mg [black squares]) throughout hospitalization. Red line = pulmonary artery (PA) systolic; blue line = PA mean; green line = PA diastolic; CAR = chimeric antigen receptor; MICU = medical intensive care unit.
Figure 2
Figure 2
Chest X-Ray Demonstrating Capillary Leak Secondary to Cytokine Release Syndrome Diffuse pulmonary opacities on chest x-ray, but normal pulmonary artery diastolic pressure of 10 mm Hg based on the CardioMEMS device (denoted by the red arrow).

References

    1. Brudno J.N., Kochenderfer J.N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31–46. - PubMed
    1. Ganatra S., Carver J.R., Hayek S.S. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. J Am Coll Cardiol. 2019;74:3153–3163. - PMC - PubMed
    1. Alvi R.M., Frigault M.J., Fradley M.G. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) J Am Coll Cardiol. 2019;74:3099–3108. - PMC - PubMed
    1. Hayden P.J., Sirait T., Koster L., Snowden J.A., Yakoub-Agha I. An international survey on the management of patients receiving CAR T Cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Curr Res Transl Med. 2019;67:79–88. - PubMed
    1. Abraham W.T., Adamson P.B., Bourge R.C. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–666. - PubMed